Skip to main content
PRCT logo

PRCT · PROCEPT BioRobotics Corp

Track PRCT — free
$25.74 -0.01 (-0.04%)
Market Cap
$1.48B
Shares
57.54M
Volume · Nov 19 1.51M Avg daily vol (3M) 1.3M

Price & Indicators

 

Key stats

Close
$25.75
Open
$25.30
Day range
$25.05–26.39
52-week closing range
$16.69–36.10
Average volume, 30 days
1.4M
Short interest
7.9M · 13.7% of shares · 9.0 days
Short volume, last session
68%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 4
Price history
Sep 2021 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Earnings call
Revenue rises 18% as full-year guidance continues

PROCEPT Biorobotics reported third-quarter revenue of $98.3 million, up 18% year-over-year, maintained 2026 revenue guidance of $390 to $410 million, and expects positive adjusted EBITDA in the fourth quarter.

3 source passages
Total revenue for the third quarter of 2026 was $98.3 million, representing 18% year-over-year growth. We continue to expect full-year 2026 total revenue to be in the range of $390 to $410 million, representing growth of approximately 27% to 33% compared to 2025. We also continue to expect adjusted EBITDA loss to be in the range of $35 million to $30 million for the full year, meaning we are on track for positive adjusted EBITDA in the fourth quarter of 2026. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows 19% as nine-month net loss widens 29%

PROCEPT BIOROBOTICS CORPORATION reported $275.9 million revenue for the nine months ended September 30, 2026, up 19%, while net loss increased 29% to $85.0 million; cash and cash equivalents were $218.4 million.

Revenue $98.29M ▲ 18.0% Net loss $26.52M Diluted EPS -$0.46
Read from the MD&A section
5 source passages
Revenue increased $15.0 million, or 18%, to $98.3 million during the three months ended September 30, 2026, compared to $83.3 million during the three months ended September 30, 2025, and increased $44.3 million or 19% to $275.9 million during the nine months ended September 30, 2026, compared to $231.7 million during the nine months ended September 30, 2025. We generated revenue of $275.9 million and incurred a net loss of $85.0 million for the nine months ended September 30, 2026, compared to revenue of $231.7 million and a net loss of $65.7 million for the nine months ended September 30, 2025. Net loss | (85,015) | | (65,727) | | 19,288 | 29 As of September 30, 2026, we had cash and cash equivalents of $218.4 million and an accumulated deficit of $726.6 million. PROCEPT BIOROBOTICS CORPORATION Open the document at this passage
Nov 4
Current report 8-K
Revenue rose 18% as full-year 2026 guidance was reaffirmed

PROCEPT BioRobotics reported third-quarter revenue of $98.3 million for the quarter ended September 30, 2026, up 18%, and reaffirmed full-year 2026 revenue guidance of $390 million to $410 million. Net loss was $26.5 million.

Financial results
4 source passages
SAN JOSE, Calif., November 4, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026. Total revenue of $98.3 million for the third quarter of 2026, an increase of 18% compared to the prior year period in 2025 Net loss was $26.5 million for the third quarter of 2026, compared to a loss of $21.4 million in the prior year period. The Company reiterates revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period Open the document at this passage
Oct 2
Current report 8-K
Director or officer change, or executive pay

PROCEPT BioRobotics Corporation expanded its board from nine members to ten and appointed Dr. Michael Mack as an independent Class II director effective October 2, 2026, with an initial term expiring at the 2029 annual meeting.

Sep 24
Current report 8-K Events of Sep 23
Entered into a material agreement

PROCEPT BioRobotics Corporation amended its loan agreement with Canadian Imperial Bank of Commerce, extending the Term Loan Maturity Date by 12 months, from October 1, 2027 to October 1, 2028; all other terms remain in effect.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$352.30M
Trailing 12 months
Net income (TTM)
−$114.86M
Trailing 12 months
Revenue growth YoY
+18.0%
Year over year
Operating margin
-33.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$166.60M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.9%
Year over year · more shares
Price change (1Y)
-7.8%
Trailing year
Short interest
13.7%
Latest settlement · 9.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Procept delivered 18% revenue growth, approximately 22% U.S. procedure growth, record international revenue, improved gross margin, stronger handpiece pricing and demand, substantially higher HYDROS utilization, capital and replacement progress, clinical-program progress, and a strong $221.4 million cash position. It reaffirmed 2026 guidance, expects positive fourth-quarter adjusted EBITDA, and views approximately 20% revenue growth as its 2027 starting point, but operating expenses and losses increased, U.S. system revenue was flat, greenfield placements fell short of expectations, AquaBeam utilization remained a headwind, and full-year procedures are expected near the low end of guidance.

Bullish
  • + Third-quarter revenue grew 18% year over year to $98.3 million, U.S. revenue grew 16% to $85.8 million, and U.S. procedures rose approximately 22% to more than 13,400.
Bearish
  • − U.S. system revenue was flat year over year at $24.7 million.
  • − Greenfield placements fell short of third-quarter expectations, although management attributed the shortfall largely to timing and continued to see healthy capital demand.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +30%
above
RSI (14) 75
overbought
MACD trend Positive
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +29%
trailing
6-month return −8%
trailing
YTD return −18%
this year
Relative strength −2%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $20 › 200d $23 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +26 funds added
Insider flow Distributing
Net -$114.7K over 90 days · 100% sells
Short interest Rising
13.66% of shares out · ▲ +4.8% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
233 holders — mid 3-yr range
Squeeze score 85
high risk · 0–100
Fundamentals
Strong
Revenue growth +37%
Y/Y
Gross margin 64%
expanding
EPS growth +2%
Y/Y
Free cash flow $-58.3M
Balance sheet $234.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 66%
annualized · 1-yr
Max drawdown −54%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the 8-K filed Nov 4, 2026
Revenue · full year 2026 Maintained $390M – $410M
Aug 4, 2026 $390M – $410M changed to Nov 4, 2026 $390M – $410M
prior FY $308.05M midpoint +29.8% Y/Y
Gross margin · full year 2026 Maintained 65%
Aug 4, 2026 65% changed to Nov 4, 2026 65%
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

International revenue · full-year 2026 $50M – $51M
New U.S. system average selling prices · second half of the year $480,000 – $490,000
Operating expenses · full-year 2026 $355M – $360M
Average selling price · full-year $300,000 – $325,000
Total handpiece revenue · full-year 2026 $200M – $215M
Prior guidance period ended · from the Earnings Call filed Apr 29, 2026
Total revenue · second quarter of 2026 $91M – $95M
Guided vs delivered · last 8 settled
Total revenue second quarter of 2026
guided $91M – $95M
$94.5M In line
Total revenues first quarter 2026
guided $79M – $82M
$83.13M Beat +3.3%
Total revenue full year 2025
guided $325.5M
$308.05M Miss −5.4%
Revenue full year 2024
guided $217M
$224.5M Beat +3.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+30% Bullish
RSI (14)
75 Bearish
MACD trend
Positive Bullish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $20 › 200d $23 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +26 funds added
Insider flow Distributing
Net -$114.7K over 90 days · 100% sells
Short interest Rising
13.66% of shares out · ▲ +4.8% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
233 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $17 Now $26 · 47% Range high $36
vs 200-day avg +13% vs 50-day avg +30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Handpiece average selling price $3,550 second quarter of 2026 —
U.S. average selling price for new HYDROS systems $495,000 second quarter of 2026 —
U.S. handpieces sold as percent of U.S. procedures 98% second quarter of 2026 —
U.S. HYDROS systems delivered 65 second quarter of 2026 —
U.S. procedures 13,100 second quarter of 2026 —
U.S. replacement HYDROS systems delivered 14 second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRCT
PROCEPT BioRobotics Corp
this stock
$1.48B -18.2% +37.2% — 13.7%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
233
% held
94.8%
Net QoQ
-332.6K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
194
View
Short & Settlement
Short Interest Rising
Shares short
7.9M
Days to cover
9.0d
Change
+356.6K sh
View
Short Volume
Short vol %
68%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
3.8K
Value
$76.1K
As of
Oct 23, 2026
View
Off-Exchange
Off-exchange %
37.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$114.7K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$308.1M
Net income (FY)
$-95.6M
EPS diluted
$-1.72
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
18

PROCEPT BIOROBOTICS CORPORATION reported $275.9 million revenue for the nine months ended September 30, 2026, up 19%, while net loss increased 29% to $85.0 million; cash and cash equivalents were $218.4 million.

View
Proposed Sales
Value
$92.9K
Shares
4.7K
Filed
Nov 6, 2026
View
Exempt Offerings
Offering
$85.0M
Filed
Jun 21, 2021
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
PROCEPT BioRobotics Reports Third…
Published
Nov 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
PRCT +9.5% +28.6% -7.6% +34.1% -18.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +15.0% +34.9% -1.9% +39.4% -23.1%
Key facts CIK 1588978 CUSIP 74276L105 13F (30d) 261 filings 216 filers Visit website Investor relations